29 March 2016
SUTHERLAND HEALTH GROUP PLC
(“Sutherland Health Group” or “the Company”)
ISDX Symbol: SHGP
RESULT OF GENERAL MEETING AND WITHDRAWAL FROM ISDX GROWTH MARKET
The Board of Sutherland Health Group, a national supplier of personal care, patient hygiene, sexual health and gynaecology products to customers including the National Health Service (“NHS”) announces that the resolution was duly passed at the General Meeting of the Company held today to approve the Company’s withdrawal from trading on the ISDX Growth Market.
Accordingly, the Company's shares will be withdrawn from trading on the ISDX
Growth Market at the close of business today, 29 March 2016.
As mentioned in the letter to shareholders advising of our withdrawal proposal, the Board have been investigating a number of options to allow shareholders to continue to buy and sell shares in the Company. The Board is pleased to announce that it has decided to join the Asset Match private market with effect from 30 March 2016.
Full details of the Asset Match private market will be notified to shareholders shortly.Information on Asset Match can be found by visiting www.assetmatch.com.
The Directors of the Issuer accept responsibility for this announcement
Sutherland Health Group Plc
John French, Chairman
T: 07836 722482
Alfred Henry Corporate Finance Ltd
T: 0207 251 3762
Notes to Editors:
Sutherland Health Group Plc is a national supplier of personal care; patient hygiene, sexual health and diagnostic products to the UK National Health Service (NHS) and other UK customers. Its aim is to supply innovative solutions to current health issues by studying current trends and working alongside leading professionals who also work within the health sector.
The company is committed to developing and marketing high quality brands and products that will benefit health professionals and consumers alike in many areas of health. The Group has established its own brands: Condomania® Condoms; Sutherland® Patient Hygiene and Personal Care; Lubricating Jelly; and Vision® pregnancy and gynaecology diagnostics. These products have already become established within the NHS business.
The Group is ISO and MHRA registered, and at present principally manufactures and operates within the United Kingdom.